February 25, 2019, Melbourne, Australia – Melbourne biotech to take its revolutionary peanut allergy treatment to Phase II clinical trials Aravax, a clinical stage biotechnology company focused on developing the next generation of peanut allergy immunotherapy with advantages in safety and practicality, has presented its clinical trial results at one of the world’s most prominent […]
February 13, 2019, MELBOURNE, Australia – Aravax, a clinical stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy, will present data from a recently completed Phase 1 clinical trial of PVX108 immunotherapy at the 2019 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting taking place February […]
2 May 2018, Melbourne, Victoria – Aravax has received an additional investment of $1.9M from the Australian Medical Research Commercialisation Fund (MRCF) to complete the ongoing Phase 1 clinical trial, AVX001, and progress Phase 2 plans for its novel treatment of peanut allergy, PVX108. These funds were released following Aravax’s achievement of research and development […]
29th January 2018, Seattle, United States of America –The Benaroya Research Institute in Seattle announced receipt of National Institute of Health funding to support investigations into the immune mechanisms of PVX108. The research group led by Erik Wambre (PhD) from the Benaroya Research Institute, became a collaborator of the Australian Biotechnology company Aravax in January […]
13th January 2018, California, United States of America – Australian biotechnology company Aravax presented preliminary data from the first Phase I clinical trial of its product known as PVX108 at the Gordon Research Conference on Food Allergy at Ventura Beach in California, held from the 7th-12th January 2018. The Gordon Research Conference brought together leading […]
9th January 2018, California, United States of America – Aravax, an Australian biotechnology company revolutionising peanut allergy treatment, today held the first meeting of its newly appointed Scientific Advisory Board, at the Gordon’s Research Conference on Food Allergy at Ventura Beach in California. Aravax is delighted to welcome 5 members to the Scientific Advisory Board. […]
17th November 2017 – Aravax today signed a collaborative agreement with Stanford University in California. The Stanford research group, led by Professor Kari Nadeau, will collaborate with Aravax to further explore immunological responses to Aravax’s revolutionary peanut allergy therapy, PVX108. Professor Kari Nadeau is one of the foremost experts in adult and pediatric allergy and […]
16 May 2017, Melbourne, Victoria – Australian biotechnology company Aravax has commenced clinical trials of a potentially life-changing product developed to treat sufferers of peanut allergy. Aravax’s technology uses carefully selected fragments of peanut proteins to switch off allergic reactions. The product is designed to be safer, more rapid, and more convenient than other approaches […]
20th January 2017, Melbourne, Victoria – Today Aravax established a collaboration with the prestigious Benaroya Research Institute in Seattle. The research group led by Erik Wambre (PhD) will work with Aravax on research into immunological responses to Aravax’s therapy, PVX108. PVX108 utilises peptides that represent carefully selected fragments of peanut proteins to switch off allergic […]
23 November 2015, Melbourne, Victoria – Two new Victorian medical technology companies have been awarded $9 million in venture capital funding to develop novel treatments for heart failure and peanut allergies. The companies, Cardiora Pty Ltd and Aravax Pty Ltd — spun out of the Baker IDI Heart and Diabetes Institute and Alfred Health and […]
